-----------------------------------------------------------------------------------------------------------------------------
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10
> -20-17.log
  log type:  text
 opened on:  30 Oct 2017, 15:36:57

. 
. 
. cap drop any_public*

. gen any_public = sponsor_public == 1 | collaborator_public == 1

. gen any_public_max = sponsor_public_max == 1 | collaborator_public_max == 1

. label variable any_public "Public firm (lower bound)"

. label variable any_public_max "Public firm (upper bound)"

. 
. * ------------------------------*
. * Main LPM regressions (Table 7)
. * ------------------------------*
. lpm_regs, lpm(g_lpm) estimator(regress) quietly 
Dependent variable: g_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       r
> eg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        
> b/se   &        b/se   \\
Trial start year    &      0.0038*  &      0.0038*  &      0.0038*  &      0.0038*  &      0.0050   &      0.0050   &      0.
> 0050   &      0.0050   \\
                    &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0024)   &    (0.0024)   &    (0.0
> 024)   &    (0.0024)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0097   &      0.0100   &      0.0097   &      0.0100   &      0.01
> 24   &      0.0127   &      0.0129   &      0.0131   \\
                    &    (0.0095)   &    (0.0096)   &    (0.0093)   &    (0.0094)   &    (0.0109)   &    (0.0110)   &    (0.0
> 107)   &    (0.0107)   \\
Phase 3 Clinical    &      0.0168   &      0.0166   &      0.0169   &      0.0167   &      0.0192   &      0.0189   &      0.
> 0196   &      0.0193   \\
                    &    (0.0145)   &    (0.0145)   &    (0.0143)   &    (0.0143)   &    (0.0160)   &    (0.0159)   &    (0.0
> 157)   &    (0.0157)   \\
Trial site in US=1  &      0.0126***&      0.0118***&      0.0120** &      0.0112** &      0.0132***&      0.0122***&      0.
> 0087*  &      0.0078*  \\
                    &    (0.0020)   &    (0.0021)   &    (0.0032)   &    (0.0031)   &    (0.0026)   &    (0.0028)   &    (0.0
> 035)   &    (0.0035)   \\
Drug indication for neoplasm=1&      0.1372***&      0.1373***&      0.1364***&      0.1365***&      0.1502***&      0.1502**
> *&      0.1444***&      0.1444***\\
                    &    (0.0147)   &    (0.0147)   &    (0.0120)   &    (0.0120)   &    (0.0184)   &    (0.0184)   &    (0.0
> 134)   &    (0.0133)   \\
NIH funding         &      0.0113   &      0.0128*  &      0.0111   &      0.0126*  &      0.0100   &      0.0114   &      0.
> 0080   &      0.0095   \\
                    &    (0.0064)   &    (0.0060)   &    (0.0060)   &    (0.0056)   &    (0.0078)   &    (0.0071)   &    (0.0
> 064)   &    (0.0058)   \\
Biomarker type: genomic=1&      0.2427*  &      0.2427*  &      0.2426*  &      0.2426*  &      0.2401*  &      0.2401*  &   
>    0.2397*  &      0.2397*  \\
                    &    (0.1103)   &    (0.1102)   &    (0.1105)   &    (0.1104)   &    (0.1129)   &    (0.1128)   &    (0.1
> 132)   &    (0.1131)   \\
Public firm (lower bound)&      0.0109*  &               &      0.0109*  &               &      0.0133*  &               &   
>    0.0132*  &               \\
                    &    (0.0043)   &               &    (0.0043)   &               &    (0.0059)   &               &    (0.0
> 060)   &               \\
Public firm (upper bound)&               &      0.0124*  &               &      0.0124*  &               &      0.0141*  &   
>             &      0.0140*  \\
                    &               &    (0.0048)   &               &    (0.0048)   &               &    (0.0062)   &        
>        &    (0.0062)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0017   &      0.0018   &  
>              &               &      0.0137   &      0.0136   \\
                    &               &               &    (0.0074)   &    (0.0074)   &               &               &    (0.0
> 129)   &    (0.0130)   \\
Constant            &     -7.6809*  &     -7.7058*  &     -7.6846*  &     -7.7096*  &    -10.1021   &    -10.1975   &    -10.
> 0812   &    -10.1759   \\
                    &    (2.8337)   &    (2.7885)   &    (2.8204)   &    (2.7752)   &    (4.8704)   &    (4.8595)   &    (4.8
> 834)   &    (4.8735)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       92568   &       9
> 2568   &       92568   \\
r2                  &       0.271   &       0.271   &       0.271   &       0.271   &       0.279   &       0.279   &       0
> .279   &       0.279   \\
* p<0.05, ** p<0.01, *** p<0.001

. lpm_regs, lpm(r_lpm) estimator(regress) quietly
Dependent variable: r_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       r
> eg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        
> b/se   &        b/se   \\
Trial start year    &      0.0034*  &      0.0034*  &      0.0034*  &      0.0034*  &      0.0044   &      0.0044   &      0.
> 0044   &      0.0044   \\
                    &    (0.0014)   &    (0.0013)   &    (0.0014)   &    (0.0013)   &    (0.0023)   &    (0.0023)   &    (0.0
> 023)   &    (0.0023)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0127   &      0.0131   &      0.0129   &      0.0132   &      0.01
> 53   &      0.0156   &      0.0158   &      0.0162   \\
                    &    (0.0101)   &    (0.0101)   &    (0.0099)   &    (0.0100)   &    (0.0117)   &    (0.0117)   &    (0.0
> 115)   &    (0.0115)   \\
Phase 3 Clinical    &      0.0215   &      0.0212   &      0.0217   &      0.0214   &      0.0236   &      0.0233   &      0.
> 0241   &      0.0238   \\
                    &    (0.0153)   &    (0.0153)   &    (0.0152)   &    (0.0151)   &    (0.0170)   &    (0.0169)   &    (0.0
> 168)   &    (0.0167)   \\
Trial site in US=1  &      0.0091***&      0.0081***&      0.0075** &      0.0065*  &      0.0090***&      0.0078***&      0.
> 0035   &      0.0025   \\
                    &    (0.0014)   &    (0.0015)   &    (0.0024)   &    (0.0022)   &    (0.0017)   &    (0.0019)   &    (0.0
> 024)   &    (0.0025)   \\
Drug indication for neoplasm=1&      0.1360***&      0.1362***&      0.1338***&      0.1340***&      0.1488***&      0.1488**
> *&      0.1418***&      0.1418***\\
                    &    (0.0139)   &    (0.0139)   &    (0.0111)   &    (0.0111)   &    (0.0175)   &    (0.0175)   &    (0.0
> 124)   &    (0.0124)   \\
NIH funding         &      0.0093   &      0.0111*  &      0.0088   &      0.0106   &      0.0100   &      0.0117*  &      0.
> 0076   &      0.0094*  \\
                    &    (0.0056)   &    (0.0052)   &    (0.0054)   &    (0.0051)   &    (0.0059)   &    (0.0053)   &    (0.0
> 050)   &    (0.0044)   \\
Biomarker type: genomic=1&      0.2174   &      0.2174   &      0.2173   &      0.2172   &      0.2142   &      0.2143   &   
>    0.2137   &      0.2138   \\
                    &    (0.1086)   &    (0.1085)   &    (0.1087)   &    (0.1087)   &    (0.1110)   &    (0.1109)   &    (0.1
> 112)   &    (0.1112)   \\
Public firm (lower bound)&      0.0138*  &               &      0.0138*  &               &      0.0163*  &               &   
>    0.0162*  &               \\
                    &    (0.0054)   &               &    (0.0054)   &               &    (0.0071)   &               &    (0.0
> 072)   &               \\
Public firm (upper bound)&               &      0.0154*  &               &      0.0154*  &               &      0.0171*  &   
>             &      0.0170*  \\
                    &               &    (0.0057)   &               &    (0.0057)   &               &    (0.0073)   &        
>        &    (0.0073)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0047   &      0.0048   &  
>              &               &      0.0165   &      0.0164   \\
                    &               &               &    (0.0069)   &    (0.0069)   &               &               &    (0.0
> 123)   &    (0.0123)   \\
Constant            &     -6.8957*  &     -6.9257*  &     -6.9057*  &     -6.9359*  &     -8.8324   &     -8.9462   &     -8.
> 8072   &     -8.9201   \\
                    &    (2.7655)   &    (2.7107)   &    (2.7552)   &    (2.7004)   &    (4.6835)   &    (4.6680)   &    (4.6
> 941)   &    (4.6796)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       92568   &       9
> 2568   &       92568   \\
r2                  &       0.254   &       0.254   &       0.254   &       0.254   &       0.261   &       0.262   &       0
> .262   &       0.262   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. * ------------------------------*
. * Duration regressions (Table 8)
. * ------------------------------*
. duration_regs, end_dates("actual") quietly
(7,269 observations deleted)
actual
(65,275 observations deleted)
(0 real changes made)

                    &       reg2a   &       reg2b   &       reg2c   &       reg2d   &       reg2e   &       reg2f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &       0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   \\
Trial start year=2001&      -1.739   &      -1.536   &      -1.357   &       2.619   &       2.968   &       3.063   \\
                    &     (1.593)   &     (1.588)   &     (1.863)   &     (2.418)   &     (2.412)   &     (2.408)   \\
Trial start year=2002&      -7.530***&      -7.012***&      -8.119***&      -2.567   &      -2.502   &      -2.262   \\
                    &     (1.458)   &     (1.453)   &     (1.718)   &     (2.320)   &     (2.289)   &     (2.285)   \\
Trial start year=2003&      -8.557***&      -7.939***&      -8.457***&      -5.048*  &      -4.524*  &      -4.122   \\
                    &     (1.403)   &     (1.400)   &     (1.665)   &     (2.250)   &     (2.234)   &     (2.233)   \\
Trial start year=2004&     -11.673***&     -11.095***&     -11.045***&      -6.793** &      -5.584** &      -5.162*  \\
                    &     (1.339)   &     (1.337)   &     (1.580)   &     (2.138)   &     (2.123)   &     (2.122)   \\
Trial start year=2005&     -14.630***&     -13.866***&     -14.616***&     -10.642***&      -9.682***&      -9.126***\\
                    &     (1.308)   &     (1.307)   &     (1.529)   &     (2.049)   &     (2.035)   &     (2.038)   \\
Trial start year=2006&     -16.123***&     -15.389***&     -15.479***&     -10.505***&      -9.157***&      -8.541***\\
                    &     (1.288)   &     (1.287)   &     (1.505)   &     (1.994)   &     (1.988)   &     (1.991)   \\
Trial start year=2007&     -18.335***&     -17.521***&     -18.436***&     -14.939***&     -13.576***&     -12.902***\\
                    &     (1.276)   &     (1.275)   &     (1.485)   &     (1.969)   &     (1.948)   &     (1.954)   \\
Trial start year=2008&     -19.482***&     -18.719***&     -19.746***&     -16.763***&     -15.163***&     -14.451***\\
                    &     (1.269)   &     (1.268)   &     (1.475)   &     (1.966)   &     (1.955)   &     (1.958)   \\
Trial start year=2009&     -20.624***&     -19.897***&     -21.420***&     -18.546***&     -17.094***&     -16.262***\\
                    &     (1.262)   &     (1.261)   &     (1.466)   &     (1.951)   &     (1.923)   &     (1.929)   \\
Trial start year=2010&     -22.329***&     -21.699***&     -22.817***&     -24.126***&     -22.224***&     -21.553***\\
                    &     (1.260)   &     (1.259)   &     (1.464)   &     (1.938)   &     (1.918)   &     (1.922)   \\
Trial start year=2011&     -23.997***&     -23.367***&     -24.795***&     -27.710***&     -25.517***&     -24.763***\\
                    &     (1.253)   &     (1.252)   &     (1.451)   &     (1.936)   &     (1.899)   &     (1.903)   \\
Trial start year=2012&     -25.497***&     -24.934***&     -26.306***&     -32.049***&     -29.979***&     -29.356***\\
                    &     (1.252)   &     (1.251)   &     (1.454)   &     (1.951)   &     (1.921)   &     (1.923)   \\
Trial start year=2013&     -27.596***&     -27.045***&     -29.031***&     -37.433***&     -35.204***&     -34.395***\\
                    &     (1.250)   &     (1.248)   &     (1.447)   &     (1.920)   &     (1.896)   &     (1.899)   \\
Trial start year=2014&     -30.714***&     -30.072***&     -32.565***&     -43.337***&     -42.259***&     -41.547***\\
                    &     (1.247)   &     (1.246)   &     (1.439)   &     (1.906)   &     (1.888)   &     (1.890)   \\
Trial start year=2015&     -33.995***&     -33.283***&     -36.576***&     -50.174***&     -49.695***&     -48.837***\\
                    &     (1.248)   &     (1.248)   &     (1.443)   &     (1.969)   &     (1.917)   &     (1.923)   \\
Trial start year=2016&     -35.929***&     -35.224***&     -38.845***&     -55.727***&     -53.677***&     -53.071***\\
                    &     (1.257)   &     (1.257)   &     (1.461)   &     (2.409)   &     (2.323)   &     (2.328)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       6.155***&       5.909***&       5.215***&       1.972** &       2.1
> 63***&       2.169***\\
                    &     (0.219)   &     (0.218)   &     (0.329)   &     (0.603)   &     (0.573)   &     (0.572)   \\
Phase 3 Clinical    &       9.311***&       9.430***&       6.863***&       8.772***&       9.783***&       9.763***\\
                    &     (0.252)   &     (0.250)   &     (0.394)   &     (1.289)   &     (1.261)   &     (1.255)   \\
Trial site in US    &       3.929***&       4.318***&               &               &               &               \\
                    &     (0.187)   &     (0.187)   &               &               &               &               \\
Drug indication for neoplasm&      19.078***&      18.919***&      17.945***&               &               &               \
> \
                    &     (0.263)   &     (0.262)   &     (0.367)   &               &               &               \\
Received NIH funding&      12.274***&      11.282***&      12.309***&       6.799***&       8.522***&       7.883***\\
                    &     (0.697)   &     (0.700)   &     (0.716)   &     (1.092)   &     (1.021)   &     (1.041)   \\
Public firm (lower bound)&      -6.039***&               &      -5.270***&               &      -3.931***&               \\
                    &     (0.184)   &               &     (0.277)   &               &     (0.576)   &               \\
Generous LPM        &       7.989***&       8.039***&       8.313***&               &       8.785***&       8.827***\\
                    &     (0.533)   &     (0.531)   &     (0.691)   &               &     (0.766)   &     (0.764)   \\
Public firm (upper bound)&               &      -7.232***&               &      -4.868***&               &      -4.757***\\
                    &               &     (0.189)   &               &     (0.617)   &               &     (0.588)   \\
Biomarker role (detailed): diagnosis&               &               &               &       2.676   &               &        
>        \\
                    &               &               &               &     (1.488)   &               &               \\
Biomarker role (detailed): differential diagnosis&               &               &               &       3.981***&           
>     &               \\
                    &               &               &               &     (1.188)   &               &               \\
Biomarker role (detailed): predicting drug resistance&               &               &               &      -2.045   &       
>         &               \\
                    &               &               &               &     (1.287)   &               &               \\
Biomarker role (detailed): predicting treatment efficacy&               &               &               &       4.976***&    
>            &               \\
                    &               &               &               &     (1.421)   &               &               \\
Biomarker role (detailed): predicting treatment toxicity&               &               &               &      -0.374   &    
>            &               \\
                    &               &               &               &     (1.985)   &               &               \\
Biomarker role (detailed): screening&               &               &               &       1.018   &               &        
>        \\
                    &               &               &               &     (1.583)   &               &               \\
Biomarker role (detailed): selection for therapy&               &               &               &       3.038*  &            
>    &               \\
                    &               &               &               &     (1.215)   &               &               \\
Biomarker role (detailed): disease profiling&               &               &               &       1.060   &               &
>                \\
                    &               &               &               &     (1.119)   &               &               \\
Biomarker role (detailed): monitoring disease progression&               &               &               &      -1.327   &   
>             &               \\
                    &               &               &               &     (1.492)   &               &               \\
Biomarker role (detailed): monitoring treatment efficacy&               &               &               &       1.381   &    
>            &               \\
                    &               &               &               &     (1.198)   &               &               \\
Biomarker role (detailed): monitoring treatment toxicity&               &               &               &      -4.095   &    
>            &               \\
                    &               &               &               &     (2.554)   &               &               \\
Biomarker role (detailed): not determined&               &               &               &       0.307   &               &   
>             \\
                    &               &               &               &     (2.495)   &               &               \\
Biomarker role (detailed): prognosis&               &               &               &       0.383   &               &        
>        \\
                    &               &               &               &     (1.375)   &               &               \\
Biomarker role (detailed): prognosis - risk stratification&               &               &               &       0.647   &  
>              &               \\
                    &               &               &               &     (1.735)   &               &               \\
Biomarker role (detailed): risk factor&               &               &               &       0.066   &               &      
>          \\
                    &               &               &               &     (1.156)   &               &               \\
Biomarker role (detailed): staging&               &               &               &      -4.423***&               &          
>      \\
                    &               &               &               &     (1.324)   &               &               \\
Biomarker role (detailed): toxicity profiling&               &               &               &       7.736   &               
> &               \\
                    &               &               &               &    (10.271)   &               &               \\
Constant            &      38.854***&      39.368***&      44.274***&      60.064***&      60.681***&      60.951***\\
                    &     (1.251)   &     (1.249)   &     (1.438)   &     (1.775)   &     (1.778)   &     (1.779)   \\
N                   &       52929   &       52929   &       27861   &        8453   &        9327   &        9327   \\
r2                  &       0.326   &       0.332   &       0.294   &       0.199   &       0.183   &       0.185   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. 
. /*
> * ------------------------------*
> * Appendix reg table: (Table A11)
> * ------------------------------*
> lpm_regs, lpm(g_lpm) estimator(logit) margins quietly
> lpm_regs, lpm(r_lpm) estimator(logit) margins quietly
> */
. 
. 
. 
. log close
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10
> -20-17.log
  log type:  text
 closed on:  30 Oct 2017, 15:37:11
-----------------------------------------------------------------------------------------------------------------------------
